<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04044664</url>
  </required_header>
  <id_info>
    <org_study_id>NYX-783-2004</org_study_id>
    <nct_id>NCT04044664</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder</brief_title>
  <official_title>A Study to Evaluate the Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aptinyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aptinyx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic
      Stress Disorder population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a 10 to 12-week study, including a 1 to 3-week screening Period, followed
      by a double-blind, randomized, placebo-controlled, parallel-group Treatment Period, and a
      1-week follow-up Period. Subjects eligible for the study will be randomized to receive either
      NYX-783 (4-weeks) or placebo (4 or 8-weeks).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 25, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive placebo or NYX-783.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition)) Total Score and Subscores</measure>
    <time_frame>From baseline to week 4 and Week 4 to Week 8</time_frame>
    <description>Change in CAPS-5 total score and Subscores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCL-5 (PTSD-Checklist for DSM-5)</measure>
    <time_frame>From baseline to week 4 and Week 4 to Week 8</time_frame>
    <description>Assess the effect of NYX-783 compared to placebo in changes of symptoms as measured by PCL-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSQI (Pittsburgh Sleep Quality Index) Global Score</measure>
    <time_frame>From baseline to week 4 and Week 4 to Week 8</time_frame>
    <description>Assess the effects of NYX-783 compared to placebo in changes in sleep quality as measure by the PSQI Global Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSQI-A (Pittsburgh Sleep Quality Index-Addendum) Global Score</measure>
    <time_frame>From baseline to week 4 and Week 4 to Week 8</time_frame>
    <description>Assess the effects of NYX-783 compared to placebo in changes in sleep quality as measure by the PSQI-A Global Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BAC Symbol Coding (Brief Assessment of Cognition)</measure>
    <time_frame>From baseline to week 4 and Week 4 to Week 8</time_frame>
    <description>Assess the effect of NYX-783 compared to placebo in changes in cognitive function as measured by the BAC Symbol Coding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-S (Clinical Global Impression - Severity)</measure>
    <time_frame>From baseline to week 4 and Week 4 to Week 8</time_frame>
    <description>Assess the effect of NYX-783 compared to placebo in the change in global clinical severity of PTSD symptoms as measured by the CGI-S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS (Hospital Anxiety and Depression Scale)</measure>
    <time_frame>From baseline to week 4 and Week 4 to Week 8</time_frame>
    <description>Compare NYX-783 vs. placebo in the changes in levels of anxiety and depression as measured by the HADS</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NYX-783 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NYX-783 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Matching placebo capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NYX-783</intervention_name>
    <description>NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).</description>
    <arm_group_label>NYX-783 High Dose</arm_group_label>
    <arm_group_label>NYX-783 Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A primary diagnosis of PTSD (DSM-5 criteria, APA 2013) with the primary traumatic
             event occurring ≥12 months prior to screening.

          -  PCL-5 ≥38 at screening.

          -  CAPS-5 total score ≥30 at screening.

        Exclusion Criteria:

          -  Complex PTSD.

          -  Trauma focused psychotherapies.

          -  Primary traumatic event occurred prior to 2001.

          -  Primary traumatic event was followed by further major traumatic life episodes.

          -  Other psychiatric disorders that is the primary focus of treatment or
             followed/worsened since exposure to the trauma (except for major depressive disorder
             or anxiety disorders that followed exposure to the trauma or an anxiety disorder that
             showed a worsening after trauma)

          -  Current use of medications with primarily central nervous system activities

          -  Other clinically significant medical histories that may interfere with completing the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Imperial</city>
        <state>California</state>
        <zip>92251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <zip>32591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60619</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>11516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78737</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aptinyx Clinical Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

